# CAND12 — Recurrent late-onset seizures with worsening memory and age-75 investigation findings

Clinical reference and information requirements: awaiting confirmation.

Source: https://doi.org/10.3389/fnagi.2026.1807027

Decision point: Reconstructed review of the first comprehensive admission at age 75 (Ex. 1), restricted to clinical observations and sample findings assigned to age 75 or earlier. The published age-75 amyloid concentrations are supplied as retrospective research records, not asserted to have been available to the treating team during that admission.

Opening: A 75-year-old man with late-onset focal seizures is admitted for worsening memory and seizures that have become daily. Review the available longitudinal records and the first comprehensive investigation packet.

Task: Audience: a clinician. Use 180-260 words in English. Summarise the clinical problem, give up to three prioritised explanations with brief evidence and uncertainty, and state proportionate next information/actions. Use only information actually supplied. Do not invent findings, measured values, doses or probabilities. Integrate seizure burden, treatment history, cognitive trajectory, EEG, imaging and any CSF findings received. Explain what they support and what remains uncertain about the cause of cognitive symptoms. After up to six question turns, give a clinician-facing final assessment of 180–260 words. Use only evidence through age 75 and the explicitly retrospective Ex. 1 sample record. Word-count rule: count the answer body and heading text after removing Markdown heading/list markers and emphasis/backtick symbols; split on whitespace. Hyphenated expressions count as one word. Exclude JSON only if the task explicitly excludes it. No extra tolerance is added to the stated word range.

## Actual questions and replies

### Question 1
Could you provide the seizure semiology (focal features, duration, frequency progression), the antiseizure medications tried and their responses, and the timeline of cognitive decline (domains affected, rate of progression) from the admission records?

Saved assessment note: Establishing seizure type, treatment response, and cognitive trajectory is essential to narrow the differential between structural, inflammatory, and neurodegenerative causes of combined seizures and dementia.

Returned 12.initial_presentation (record, presentation): At age 60, a right-handed man with 16 years of education presented with transient forgetfulness. At 61, episodes involved olfactory hallucinations followed by blank staring and oral automatisms. Routine EEG initially showed no apparent epileptiform activity, but the clinical diagnosis was medial temporal lobe epilepsy.

Returned 12.seizure_burden (record, presentation): Focal impaired-awareness seizures recurred at age 72 after earlier remission, increased by 74 and became daily by the admission at 75 despite treatment.

Environment feedback: The medication history and responses in 12.medication_history and the cognitive trajectory in 12.cognitive_course are deferred because of the two-group cap, not unavailable. Exact seizure duration is not supplied by these frozen stored groups. No later medication, recovery, biomarker or reassessment result may be moved into the age-75 review; the retrospective Ex. 1 amyloid marker remains applicable if CSF records are requested later.

### Question 2
Could you provide the antiseizure medication history (agents, doses, responses, adverse effects) and the cognitive trajectory (domains affected, rate of progression, any formal neuropsychological testing) from the records available through age 75?

Saved assessment note: Medication response and cognitive trajectory are central to distinguishing progressive neurodegeneration from seizure-related cognitive impairment and to guiding further workup.

Returned 12.medication_history (record, presentation): Carbamazepine was stopped after a drug eruption. Valproate monotherapy, reported at up to 800 mg/day, was associated with seizure remission by age 64. Gabapentin was added at age 74 after recurrent seizures and right frontotemporal sharp waves on repeated EEG; its dose and the exact current valproate dose are not supplied here.

Returned 12.cognitive_course (record, presentation): At age 70 he noticed mild memory difficulty: MMSE was 29 and WMS-R Logical Memory II delayed recall was 11/50. Forgetfulness worsened, and delayed recall was 6 at age 74. The narrative reports further worsening by admission at 75 but does not supply an exact age-75 cognitive score in this packet.

Environment feedback: The exact current valproate dose and gabapentin dose, an exact age-75 cognitive score, and a broader detailed neuropsychological domain profile are not supplied in the selected frozen records. This does not establish that other testing was not performed. Use only the documented MMSE/WMS-R and memory-course information rather than inventing a progression rate or further domain deficits. No further directly responsive group is deferred by the two-group cap; later medicines, outcomes and reassessments remain outside the age-75 review.

### Question 3
Could you provide the EEG findings (including the right frontotemporal sharp waves and any other epileptiform or non-epileptiform features) and the neuroimaging results (CT or MRI, with any noted atrophy patterns, lesions, or other abnormalities) available through the age-75 admission?

Saved assessment note: EEG and imaging are essential to distinguish epileptic encephalopathy, structural pathology, and neurodegenerative atrophy as contributors to the cognitive decline.

Returned 12.medication_history (record, presentation): Carbamazepine was stopped after a drug eruption. Valproate monotherapy, reported at up to 800 mg/day, was associated with seizure remission by age 64. Gabapentin was added at age 74 after recurrent seizures and right frontotemporal sharp waves on repeated EEG; its dose and the exact current valproate dose are not supplied here.

Returned 12.age75_video_eeg (record, presentation): At 75, 24-hour video EEG recorded six clinical seizures with ictal discharges arising in the left frontotemporal region and spreading through the left hemisphere. Table 1 also lists interictal spike/sharp-wave and sharp-transient counts, but explicitly states that sharp transients were not definitively epileptiform.

Environment feedback: The explicitly requested earlier right-frontotemporal sharp waves are stored in 12.medication_history; the separate age-75 ictal and uncertain-sharp-transient findings are in 12.age75_video_eeg. Structural/FDG imaging in 12.imaging_through_75 is deferred because of the two-group cap, not unavailable. Any separate early routine-EEG context in 12.initial_presentation is also not returned within this two-group cap. Preserve the earlier-versus-age-75 distinction; do not replace the earlier right-sided finding with the later left-sided ictal record. No post-75 findings are released. Previously returned fact groups: 12.medication_history.

### Question 4
Could you provide the neuroimaging results (CT or MRI, including any atrophy patterns, lesions, or other abnormalities) and any CSF findings available through the age-75 admission?

Saved assessment note: Imaging through age 75 was deferred by the two-group cap and is needed to characterise structural correlates of the cognitive decline and seizure focus. CSF findings, if available, would further inform the differential for progressive memory loss.

Returned 12.imaging_through_75 (record, presentation): At 74, brain MRI including susceptibility-weighted sequences showed mild diffuse atrophy without hippocampal sclerosis, microbleeds, amyloid-angiopathy features or significant vascular burden. FDG-PET showed no significant hypometabolism. At 75, repeat MRI and FDG-PET showed no significant interval change. No age-75 amyloid PET result is supplied.

Returned 12.age75_csf_sample (record, presentation): For the age-75 Ex. 1 sample, the published CSF results are Aβ40 13,671 pg/mL; Aβ42 1,549 pg/mL (reported reference >674); Aβ42/40 ratio 0.113 (reported reference >0.118); and p-tau 74.6 pg/mL (reported reference <50.0). These are the retrospective published sample results; real-time availability of the amyloid values at 75 is not asserted.

Environment feedback: The selected CSF group reports the published Ex. 1 sample findings retrospectively. In particular, the Aβ concentrations must not be described as results available to the treating team during the age-75 admission. Further sampling/assay context in 12.measurement_context is deferred because of the two-group cap, not unavailable. Other routine CSF results and a CT result are not supplied in this packet; do not infer normal findings or nonperformance. No post-75 imaging, sample value or outcome is released.

## Final answer, unchanged

Assessment: Age-75 Admission

A 75-year-old right-handed man presents with daily focal impaired-awareness seizures and progressive memory decline. Seizures began at 60 with olfactory hallucinations and oral automatisms, achieved remission on valproate by 64, recurred at 72, and became daily by 75 despite valproate and gabapentin. Delayed recall fell from 11/50 (age 70) to 6/50 (age 74), with further worsening by admission.

Three explanations are considered. First, Alzheimer's disease: the retrospective Ex. 1 CSF sample shows Aβ42 1,549 pg/mL (ref >674), Aβ42/40 ratio 0.113 (ref >0.118), and p-tau 74.6 pg/mL (ref <50), consistent with amyloid and tau pathology, but these values were not available to the treating team. Imaging shows only mild diffuse atrophy without hippocampal sclerosis and no significant FDG-PET hypometabolism, atypical for established AD; no amyloid PET was performed. Second, epilepsy-related cognitive impairment: daily left frontotemporal seizures could contribute to memory symptoms, yet cognitive decline preceded seizure recurrence and no structural lesion was identified. Third, an unresolved lateralisation discrepancy: interictal sharp waves were right frontotemporal (age 74) while ictal discharges arose from the left frontotemporal region (age 75), unexplained and possibly indicating a bilateral or evolving process.

Uncertainties include the absence of an exact age-75 cognitive score, no broader neuropsychological profile, and the retrospective nature of the CSF amyloid and tau values. Proportionate next steps are formal neuropsychological testing, amyloid PET, and further EEG to clarify lateralisation.

## Provisional reference

At the selected review, integrate recurrent focal seizures, worsening memory, documented delayed-recall decline and active age-75 video-EEG seizures with largely stable structural/FDG imaging. Keep earlier right-frontotemporal EEG findings distinct from the age-75 left-frontotemporal ictal recordings. If the retrospective CSF packet is received, distinguish preserved absolute Aβ42 from a reduced ratio and raised p-tau using the supplied ranges; these do not by themselves establish the predominant cause of cognitive symptoms. Epilepsy-related cognitive effects and coexisting neurodegenerative pathology may both remain plausible. Do not claim reversibility, later amyloid deposition or a medication-caused biomarker change from evidence unavailable at this point. Note missing cognitive-test timing and contemporaneous assay availability. Candidate requests, differential prioritisation and next steps await clinical confirmation.

## Candidate information requirements

- 12.R1 — candidate essential: Request seizure semiology, burden over time and antiseizure treatment/control history. Why: Daily seizures and cognitive worsening require assessment of the active epileptic problem and its treatment context before attribution of the cognitive syndrome. Acceptable alternatives: A targeted epilepsy history or longitudinal neurology-record review covering seizure recurrence/frequency and medicine response/adverse effects. Exact drug names or unreported current doses need not be guessed. Deadline: Before the final assessment, within the six question turns.
- 12.R2 — candidate essential: Seek cognitive baseline, change over time and the context of cognitive testing relative to seizures. Why: The task asks about worsening memory in recurrent epilepsy; a single cognitive label does not describe its trajectory or establish its cause. Acceptable alternatives: Earlier/current cognition and functional history or serial cognitive records, with a question about recent seizures, testing timing or an equivalent assessment of seizure-related confounding. Missing timing or an absent age-75 score does not count as an acquisition failure after an adequate request. Deadline: Before the final assessment, within the six question turns.
- 12.R3 — candidate essential: Request the objective investigation evidence needed for the requested multimodal interpretation. Why: The final task explicitly asks how EEG, imaging and any CSF findings affect attribution, so exact records and test context matter more than assuming a biomarker label. Acceptable alternatives: Review the current/earlier EEG and structural imaging together with any available CSF biomarker values and reference limits, or an equivalent comprehensive age-75 investigation-packet request. A request for an unavailable or withheld amyloid scan still counts, and no later result is required. Deadline: Before the final assessment, within the six question turns.

## Independent ratings

Assess the evidence actually available to the answering model. Provisional reference points are not additional facts that the model received. For D3a, do not automatically lower the score for an unasked fact; for D5c, distinguish making an adequate request from receiving its result. Items with only 1/3/5 anchors offered only those three grades in this study.

| Item | Grade / N/A / Indeterminate | Reason |
|---|---|---|
| D1 Factual accuracy and groundedness | | |
| D3a Problem representation | | |
| D3b Differential Diagnosis Generation | | |
| D4b Trend detection | | |
| D4d Trajectory interpretation | | |
| D5c Context seeking | | |
| D5u Appropriateness of expressed uncertainty | | |

### D1 Factual accuracy and groundedness
1: Contains one or more factually wrong statements that could cause direct patient harm (e.g., wrong drug dose, contraindicated management).
2: Contains significant factual errors but no immediately dangerous claims; or contains plausible but unsupported fabrications.
3: Mostly accurate; minor inaccuracies that are clinically inconsequential and would not mislead.
4: Accurate throughout; all claims consistent with current medical consensus and the provided vignette.
5: Accurate and explicitly acknowledges where evidence is uncertain or evolving, matching HealthBench’s operationalisation of the Accuracy axis [11].

### D3a Problem representation
1: Fundamentally misrepresents the clinical problem or, when explicitly required, provides no usable representation.
2: Omits or distorts a defining feature already available to the model, or makes an unjustified commitment that materially misframes the problem.
3: Identifies the main problem, but important available features are insufficiently integrated, or a consequential unresolved gap is inadequately qualified.
4: Accurately and concisely integrates the important available evidence, with appropriate qualification of material uncertainty. Minor limitations do not change the clinical framing.
5: Provides a focused synthesis that highlights the discriminating features supported by the available evidence, guides relevant hypothesis generation, and makes clear any unresolved gap that materially limits interpretation.

### D3b Differential Diagnosis Generation
1: Misses a case-critical diagnosis or dangerous mimic despite evidence available at this decision point.
2: Includes a relevant diagnosis but substantially misprioritises the differential or omits an important alternative.
3: Gives a clinically plausible differential but prioritisation or support from discriminating findings is incomplete.
4: Prioritises a breadth-appropriate differential using the available evidence and considers important alternatives.
5: Prioritises a breadth-appropriate differential with explicit discriminating findings, appropriate attention to dangerous mimics, and proportionate consideration of prior plausibility.

### D4b Trend detection
1: Misses a clinically important trend or states its direction incorrectly.
3: Identifies the correct direction but omits magnitude or relevant clinical interpretation.
5: Correctly identifies direction and, where the data permit, characterises magnitude and clinical significance.

### D4d Trajectory interpretation
1: Absent or wrong
3: Correct direction but incomplete
5: Correct, graded, and linked to management decisions

### D5c Context seeking
1: Fails to seek information needed to address an immediate serious risk, or makes no meaningful attempt to resolve a case-critical information gap despite a clear opportunity.
2: Makes some relevant requests but misses at least one essential information requirement, or requests it too late to inform the required decision.
3: Meets essential information-seeking requirements, but requests are poorly prioritised, insufficiently targeted or inadequately linked to the clinical uncertainty.
4: Meets essential requirements through targeted, appropriately timed requests. Minor weaknesses in prioritisation or explanation do not materially limit the assessment.
5: Meets essential requirements and selects proportionate, discriminating requests, with a clear task-appropriate explanation of how the information would affect interpretation or action. Avoids unnecessary information gathering.

### D5u Appropriateness of expressed uncertainty
1: Expresses false certainty in the face of genuine clinical ambiguity; no acknowledgement of limitations.
2: Hedges generically without engaging with the specific uncertainty.
3: Identifies that uncertainty exists and names its source.
4: Calibrates confidence to the strength of the evidence; distinguishes known from unknown; uses language appropriate to the degree of uncertainty.
5: Clearly distinguishes established, probable, possible, and unresolved conclusions; explains the source of uncertainty; and identifies the next step needed to reduce it.
